Ignyta (RXDX) Posts Q1 Loss of $1.15/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Ignyta Announces First Quarter 2015 Company Highlights and Financial Results
May 11, 2015 4:00 PM EDTSAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced company highlights and financial results for the first quarter ended March 31, 2015.
We continue to make substantial progress toward our goal of becoming a leading precision oncology biotechnology company, and we are excited about our potential to develop first-in-class and best-in-class precision medicines to help cancer patients with unmet needs, said Jonathan Lim, M.D., Chairman and CEO of Ignyta. Our March 2015 acquisition of four development stage programs from Teva was transformational, enabling us to leverage our existing precision... More
